Roles of the Nrf2/HO-1 pathway in the anti-oxidative stress response to ischemia-reperfusion brain injury in rats

L.-J. JIANG¹, S.-M. ZHANG¹, C.-W. LI², J.-Y. TANG³, F.-Y. CHE¹, Y.-C. LU⁴

¹Department of Neurology, Linyi People’s Hospital Affiliated to Shandong University, Linyi City, Shandong Province, China
²Pharmacy Intravenous Admixture Service, Zhangqiu People’s Hospital, Ji’nan, China
³Department of Neurology, Qianfoshan Hospital Affiliated to Shandong University, Ji’nan, China
⁴Department of Central Laboratory, Linyi People’s Hospital Affiliated to Shandong University Linyi City, Shandong Province, China

Abstract. – OBJECTIVE: The aim of this study was to investigate the roles of the Nrf2/HO-1 pathway in the responses to the oxidative stress created by ischemia-reperfusion brain injury in rats.

MATERIALS AND METHODS: 54 healthy, adult, male SD rats were included in the study. Eighteen (18) rats were placed in the sham group. The ischemia-reperfusion model was created in the other 36 rats, among which 18 received injections of Nrf2 agonist before the surgery. The suture method was used to create artery occlusions in the right brain of the rats; and reperfusion was done after 90-minute ischemia (MCAO); while no suture was inserted in the sham group. At 3, 6, 12, 24, 48 and 72 hours after the modeling, their neurological functions were evaluated. Also, at different time points, rats were decapitated, and their fresh brain tissues were used to detect the infarct volume percentages by TTC staining and the brain water contents by the dry-wet weight method. The SOD contents in the brain tissue were measured by Xanthine oxidase assay. RT-PCR was used to detect the mRNA expression of HO-1 in the brain tissues, and western blot method was used to detect the expression level of HO-1 and Nrf-2.

RESULTS: The rats in the sham group had no obvious neurological defects; while those in the MCAO group showed significant neurological defects at all time points. The MCAO group had higher neurological evaluation scores than the sham group. TTC staining showed that infarct in the MCAO group kept increasing over time and peaked at 24h. Measurements of SOD found that the sham group had the highest SOD among the three groups, and showed no significant fluctuation over time. The MCAO group had much lower SOD activities than the sham group at all the time points. The higher the level of HO-1mRNA and protein expression in the brain tissue of rats in each group, the higher the degree of brain injury, but the lower the level of Nrf2 protein expression and the lower degree of brain injury. Nrf2 agonist markedly improved all these indicators in the rats which underwent the MCAO surgery.

CONCLUSIONS: The expression of HO-1 after ischemia-reperfusion brain injury may contribute to the increased infarct volume. Activation of Nrf2 could improve the prognosis of ischemia-reperfusion brain injury.

Key Words: Ischemia-reperfusion brain injury, Nrf-2, HO-1.

Introduction

Ischemic or hemorrhagic cerebrovascular disease is a type of severe neurological disease. Each year about 1 million people die of cerebrovascular diseases in our country. About 75% of those who survive have varying degrees of disabilities or complete loss of self-care abilities, seriously affecting the quality of patients’ lives. Ischemia-reperfusion brain injury is a complex pathological process; and its underlying mechanism connects and interact. The current research results showed that many mechanisms were involved in ischemia-reperfusion brain injury. They were interrelated and affected one another, forming a “mesh” structure, and the “main pathway” of the pathogenesis remained unclear. Therefore, investigating the incidence of ischemia-reperfusion injury is still the main focus of research in this field.

The Keapl-Nrf2/ARE pathway was one of the important mechanisms for intracellular antioxidant function and cytotoxic defense. It had a wide range of cytoprotective functions, including anti-tumor, anti-oxidative stress, regulating GSH synthesis, anti-apoptotic, anti-inflammatory, anti-atherosclerotic, regulating heart cerebrovascula-
lar reactivity and neuroprotection. Transcription factor NFE2 related factor 2 (Nrf2) and its cytoplasmic adapter protein Keap1 are the central regulators of cellular antioxidant responses. By interacting with the antioxidant response element ARE, Nrf2 appears to be an important effector molecule for the maintenance of healthy blood vessels and the prevention of cardiovascular diseases through NO-mediated signal transduction. Nrf2 is also an important effector molecule to lower the risk of stroke by antagonizing NO-induced apoptosis. Upregulation of Nrf2 plays a protective role in neurons by inducing some antioxidant enzymes and detoxification enzymes to accelerate the enzymatic reactions, as well as by increasing the expression levels of GSH and SOD and other antioxidants. Heme oxygenase-1 (HO-1) pathway is an important oxidative stress pathway. In tissues with ischemic damages, the over activation of the HO-1 pathway can have protective functions. As a rate-limiting enzyme in the metabolism of heme, HO catalyzes the oxidative degradation of heme into carbon monoxide (CO), iron and biliverdin. Subsequently, biliverdin is converted to bilirubin by bilirubin reductase. There are three subtypes of HO, namely HO-1, HO-2, and HO-3. HO-1 (Hsp32) could be induced by stress in almost every cell type. A key regulatory element of HO-1 expression is Bach-1, which is a highly conserved leucine zipper protein with a heme binding site. Using small interfering RNA (siRNA) to target Bach-1 significantly reduced the mRNA and protein level of Bach-1, and induced the expression of HO-1. Based on all these previous researches, we have further investigated the functions of the Nrf2/HO-1 pathway in ischemia-reperfusion brain injury, in an effort to provide theoretical support for clinical treatment.

**Materials and Methods**

**Experiment Animals**

Fifty-four SPF grade healthy male adult SD rats with weights between 250 and 300 g were purchased from Medical Science Experiment Animal Institute of Chinese Academy of Medical Sciences. This study obtained the Ethics Committee’s approval of Linyi People’s Hospital Affiliated to Shandong University.

**Materials and Equipment**

The following materials and equipment were use: Total SOD detection kit (Nanjing Jiancheng Biological Engineering Technology Co., Ltd.); 1 M Tris-Hcl (pH = 6.8), DNA Marker, Tris, Trizol reagent, Diethyl dicarbonate ester, PVDF membrane (0.45 µM), PMSF (phenylmethylsulfonyl fluoride), Western blotting blocking buffer, Antibody dilution buffer for Western blotting, IP cell lysis buffer, Hypersensitivity ECL chemiluminescence kit, Rabbit anti-rat β-actin monoclonal antibody (Beyotime Biotechnology Co. Ltd, Shanghai, China); 37°C constant temperature incubator, Vortex mixers (Beijing Liuyi Scientific Instrument Factory, Beijing, China); 4 × dNTP, DMSO, EB, Reverse transcriptase, Ribonuclease agonist (Sigma-Aldrich, St. Louis, MO, USA); 40% Aer-Bis (39: 1), 0.1MPBS, BCA protein assay kit, SDS (sodium dodecyl sulfate), β-mercaptoethanol, AP (ammonium persulfate), Horseradish peroxidase-labeled goat anti-rabbit IgG antibody, Mortar, Edetate disodium, Isopropyl alcohol, Chloroform, Ethanol, Tween solution, Glycine, Glyceral, Methanol (Chongqing Dingguo Biological Company, Chongqing, China); FBS (Promega, Madison, WI, USA); PageRuler Prestained Protein Ladder (Thermo Scientific, Waltham, MA, USA); PCR thermocycler, Electrophoresis apparatus, Electrophoresis tank, Gel scanning and analysis system, Power supply (Bio-Rad, Hercules, CA, USA); Taq DNA polymerase, TEMED (Amresco, Solon, OH, USA); Glass homogenizer (Zhuozhou Changhong Glass Instrument Factory, Zhuozhou, China); Ultra-low temperature freezer (Sanyo, Tokyo, Japan); Low temperature centrifuge CR21 (Hitachi, Tokyo, Japan); Multi-functional microplate reader Model 680 (Bio-Rad, Hercules, CA, USA); High-speed refrigerated centrifuge (Eppendorf, Hamburg, Germany); Gel imaging system (Kodak, Tokyo, Japan);BORIC acid (Southwest Chemical Reagent Company, Chongqing, China); Nrf2 agonist, Agarose (Sigma-Aldrich, St. Louis, MO, USA); Horizontal electrophoresis tank (Beijing Liuyi Scientific Instrument Factory, Beijing, China); Image analysis system software (Imaging, Eagan, MN, USA); Rabbit polyclonal anti-rat Nrf2 (Bioworld, USA); Bromphenol blue (Amresco, Solon, OH, USA).

**Methods**

Animal grouping and drug administration

Fifty-four healthy adult male SD rats, weighing between 250 to 300 g, were used in this study. All rats were numbered and grouped by the random number table method. Eighteen rats were placed in the sham group. The ischemia-reperfusion model was created in the other 36 rats, among which 18 rats received injections of Nrf2 agonist before the sur-
surgery. At 3h, 6h, 12h, 24h, 48h and 72h after the modeling, their neurological functions were evaluated. A modified suture method was used to create MCAO model on the right side of the rats. The rats were fasted 12 hours before the operation but the water was allowed. Reperfusion was done 90 minutes after ischemia. Hereinafter the model group would be referred to as the MCAO group. The rats in the sham group received the same surgery operations except that no suture was inserted. The drug-administered group received an intraperitoneal injection of Nrf2 agonist at the dose of 20 mg/kg at 48h and 24h before the MCAO, hereinafter referred to as MCAO + Nrf2 agonist group. The rats in the sham group and the MCAO got 3 ml intraperitoneal injection of 3 ml saline at the same time points.

Creation of experiment animal model

Preoperative Preparation

The animals were fasted 12 hours before the surgery, but the water was allowed. Fishing line with a diameter of about 0.26 mm was used to make sutures. The head ends were made spherical with fire, and the length of the sutures was about 40 mm. A black marker was used to mark the 18-24 mm part. The sutures were air dried, disinfected with 75% alcohol and stored in physiological saline.

Model Creation

Intraperitoneal injection of an appropriate amount of 3.5% chloral hydrate (10 ml/kg) was used to anesthetize the rats. Right common carotid artery, internal and external carotid arteries were exposed and separated. Ligation of the common carotid artery was done at the proximal end, about 0.7 cm to the bifurcation. A loose spare operating suture line was placed between this surgical ligation and the bifurcation. After ligation of the external carotid artery and clipping the internal carotid artery, a small incision was cut between the bifurcation and the spare suture line. A prepared suture was inserted till the middle of the part that was marked by a black marker. After the spare suture line and the suture had been tightened together, the clip on the internal carotid artery was loosened, and the excess suture line was cut off. The incision was stitched and disinfected. The same operations except that no suture was inserted, were performed on the sham group. After the surgeries, the rats were placed into clean cages, kept warm, well fed and given enough water. Ninety minutes after the blocking ischemia, the suture was gently pulled out and reperfusion occurred.

Measurement of infarct volume percentages

After the rats had been anesthetized, they were decapitated and their brains were separated on the ice. The brains were frozen in a -20°C refrigerator for 20 minutes. Each brain was cut into 5 sections. The sections were then placed in 2% TTC with a foil cover and incubated in a 37°C incubator for 15-30 minutes, making sure the brain tissues uniformly contact the staining solution. A digital camera and the image analysis system were used for the image acquisitions and analyses. Infarct volume percentage (%) = the calibrated infarct volume / volume of the contralateral hemisphere.

Determination of brain water contents

After the animals had been anesthetized and decapitated, the entire brain was taken out. 4 mm frontal pole was removed with coronal cut and reserved for brain water content determination. Each foil piece was weighed beforehand (W1). Each brain tissue was wrapped in a piece of foil and the total weight was demined (W2). Wet weight = W2-W1. The brain tissues wrapped in foils were then dried. After the packages had gone back to room temperature, their weights were taken and referred to as W3. Dry weight = W3-W1. The brain water content was calculated by the formula (W3-W1) / (W2-W1) × 100%.

Determination of brain tissue SOD contents

Animals were sacrificed and decapitated to remove the right brains. An appropriate amount of brain tissues was set aside after the cerebellum and medulla oblongata were removed. The brain tissue was weighed and put in a pre-cooled (at -20°C) glass homogenizer. Precooled saline was added and the homogenization was carried on an ice tray until no suspended solids were visible. The homogenate was transferred to a centrifuge tube (10 m) with a pipette and centrifuged at 4°C at 3,500 rpm for 15 minutes. The supernatant was used to measure the SOD content. All operations followed the manufacturer’s instructions and the readings were taken at the wavelength of 550 nm.

Evaluations of neurological functions

Neurological functions were evaluated at 3 h, 6 h, 12 h, 24 h, 48 h and 72 h after successful surgeries. Rats with 2, 3, 4 points were included in the MCAO group. The evaluation was based on the following six-point scale of improved Lon-ga assessment: 0 point, no neurological defect; 1 point, failure to fully extend the contralateral (paralyzed) side forelimb; 2 points, failure to ex-
tend the contralateral (paralyzed) side forelimb; 3 points, slight circular motion to the contralateral (paralyzed) side (big circle); 4 points, obvious circular motion to the contralateral (paralyzed) side (small circle); 5 points, falling to the contralateral (paralyzed) side. The higher the score, the more severe the behavioral disorders.

Sample preparation and procedures of RT-PCR
The total RNAs were extracted and the concentrations and integrities were determined according to the instructions of the Trizol kit. PCR amplification contained 1 μl cDNA (obtained by reverse transcription of RNA), 1 μl upstream primer, 1 μl downstream primer and 12.5 μl master mix. Double distilled water was used to bring the volume to 25 μl. The PCR reaction conditions for Nrf2 and HO-1 were: 94°C denaturation for 5 min, 30 cycles of 95°C for 30 seconds, 57°C for 30 seconds, and 72°C for 30 seconds. The RT-PCR primers were synthesized by Shanghai Sangob Biotech. The primer sequences were: HO-1 gene primer: The upstream sequence: 5’-AGCCCACCAGTTCAACA-3’; downstream sequence: 5’-TGCCAACAGGAGCTGAGAG-3’. The Amplified fragment was 321 bp, β-actin gene primer: The upstream: 5’-GAGACCTTCAACCCCATCC-3’ downstream sequence: 5’-CCA-CAGGATTCCTACCCCAA-3’. The Amplified fragment was 446 bp.

Sample preparation and procedures of Western blotting
The animals were anesthetized and supine fixed. Heart perfusion was done with saline (0.9% NaCl, containing 0.16 mg/ml NaCl) and heparin. Then, the rats were decapitated and their brains were removed. After cell lysis and homogenization, proteins were extracted from brain tissues with the BCA method, and then the proteins were transferred to the membrane. The membrane was incubated with the diluted primary antibody (Nrf2 1:100, HO-1 1:100, or β-actin 1:500) at 4°C for overnight. The membrane was then washed with TPBS solution with shaking for 5 min, and the wash was repeated two more times. Diluted horseradish peroxidase-labeled secondary antibodies (Nrf2 1:3000, HO-1 1:3000, or β-actin 1:5000) were added and the membrane was incubated at room temperature for 2 hours. The membrane was again washed 3 times with TPBS solution with shaking. The membrane was developed by following the instructions of the hypersensitivity ECL chemiluminescence kit. The gel scanning analysis system was used to obtain the image and to do the analysis.

Statistical Analysis
RT-PCR and Western blotting results were processed with the Image Lab software. The optical density of each band was collected and then statistically analyzed with the SPSS 12.0 statistical software (IBM, Armonk, NY, USA). Data of neurological function, infarct volume, and SOD activity were collected, and statistical analyses were conducted. Results of RT-PCR and Western blotting underwent ANOVA analysis and SNK-q test. α = 0.05. Significance was set at p<0.05.

Results
Evaluation of neurological functions
All modeled rats had a score between 2-4. The rats in the sham group had no obvious symptoms of neurological defects. The rats in the MCAO group and the MCAO + Nrf2 agonist group exhibited evident neurological defects and higher evaluation scores than the sham group at each time point. The differences were significant (p<0.05) (Table I), indicating the successful establishment of the ischemia-reperfusion model. The scores increased with time and peaked at 24h. The MCAO + Nrf2 agonist group had improved neurological functions compared with the MCAO group at each time point. They had significantly lower scores than the MCAO rats (p<0.05) (Figure 1).

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>3h</th>
<th>6h</th>
<th>12h</th>
<th>24h</th>
<th>48h</th>
<th>72h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>18</td>
<td>0.12±0.45</td>
<td>0.37±0.21</td>
<td>0.53±0.32</td>
<td>1.57±0.43</td>
<td>1.16±0.45</td>
<td>0.33±0.51</td>
</tr>
<tr>
<td>MCAO</td>
<td>18</td>
<td>3.12±0.43</td>
<td>3.68±0.51</td>
<td>4.18±0.56</td>
<td>4.58±0.42</td>
<td>3.82±0.67</td>
<td>3.02±0.42</td>
</tr>
<tr>
<td>MCAO+Nrf2 agonist</td>
<td>18</td>
<td>2.76±0.64</td>
<td>3.23±0.42</td>
<td>2.43±0.65</td>
<td>3.08±0.66</td>
<td>2.51±1.25</td>
<td>2.02±0.46</td>
</tr>
<tr>
<td>F-value</td>
<td>-</td>
<td>41.265</td>
<td>55.487</td>
<td>32.763</td>
<td>23.872</td>
<td>23.434</td>
<td>14.387</td>
</tr>
<tr>
<td>p-value</td>
<td>-</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>
Post-reperfusion Infarct volume percentages detected by TTC staining

Normal brain tissues would be red after TTC staining, while infarct would appear white. The sham group had no obvious brain infarct, while large areas of infarct were observed in the MCAO group and the MCAO + Nrf2 agonist group. The differences were significant ($p < 0.05$) (Table II), indicating that the establishment of the experimental model was successful. The MCAO group showed evident increased brain infarct volume percentage at 3h; the percentage peaked at 24h and started to decrease slowly at 48h. Compared with the MCAO group, the infarct volume percentage of the MCAO + Nrf2 agonist group was lower at each time point, and the differences were significantly difference ($p < 0.05$) (Figures 2 and 3), suggesting that the Nrf2 agonists could significantly reduce infarct volume percentages, mitigate the damages caused by cerebral ischemia and have protective effects on cerebral ischemia.

Determination of brain tissue water contents

The sham rats showed no obvious increase in the brain water content. The rats in the MCAO group had higher brain water contents than the sham group at all tested time points. The significant increase started at 3h and peaked at 24h. Slow declining started at 48h. The differences were statistically significant ($p <0.05$) (Table III). Compared with the sham group, the MCAO + Nrf2 agonist group showed no significant difference in brain water contents at 3h. Their brain water contents began to rise significantly at 6h, reached the peak at 24h and began to decline at 48h. Compared with the MCAO group, the MCAO + Nrf2 agonist group had lower brain water contents, and the differences were significant ($p < 0.05$) (Figure 4).

Determination of SOD in the brain tissues of each group

The rats in the sham group showed the highest brain tissue SOD and did not change much over time. The MCAO group and MCAO + Nrf2 agonist group both had lower brain tissue SOD activity than the sham group, and the differences were significant ($p < 0.05$) (Table IV). The SOD activity in the MCAO rats began to decrease at 3h, and did not show recovery until 72h after the surgery. The rats in the MCAO + Nrf2 group showed comparable SOD activity compared with the sham group at 3h. Their SOD activity started to show decline at 6h. Also, the MCAO + Nrf2 group showed higher SOD activity than the MCAO group at each time point with significant differences ($p < 0.05$) (Figure 5).

Table II. Brain infarct volume percentages of each group of rats (X ± SD).

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>3h</th>
<th>6h</th>
<th>12h</th>
<th>24h</th>
<th>48h</th>
<th>72h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>18</td>
<td>3.14±0.00</td>
<td>2.37±0.01</td>
<td>4.59±0.01</td>
<td>4.68±0.00</td>
<td>2.38±0.00</td>
<td>2.46±0.00</td>
</tr>
<tr>
<td>MCAO</td>
<td>18</td>
<td>24.12±2.43</td>
<td>32.68±1.51</td>
<td>38.18±1.56</td>
<td>37.58±0.42</td>
<td>43.82±3.67</td>
<td>34.38±3.8</td>
</tr>
<tr>
<td>MCAO+Nrf2 agonist</td>
<td>18</td>
<td>19.76±3.64</td>
<td>25.23±1.42</td>
<td>31.43±1.65</td>
<td>35.08±7.66</td>
<td>37.51±5.25</td>
<td>24.33±2.18</td>
</tr>
<tr>
<td>F-value</td>
<td>-</td>
<td>341.265</td>
<td>2055.487</td>
<td>5132.763</td>
<td>3223.872</td>
<td>3923.434</td>
<td>3614.387</td>
</tr>
<tr>
<td>$p$-value</td>
<td>-</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>
Nrf2/HO-1 is a key signaling pathway in Ischemia-reperfusion brain injury

Figure 2. Infarct volume percentages over time after modeling. The MCAO and MCAO + Nrf2 agonist group had the highest percentages 24 hours after the surgery. Compared with the sham group, the differences were statistically significant ($p<0.05$).

Figure 3. Results of TTC staining. Normal brain tissue showed red after TTC staining, while infarct was white. The ham group had no significant brain infarct; while large areas of infarct were observed in the MCAO group and the MCAO + Nrf-2 agonist group. The differences were significant ($p<0.05$).

Table III. Brain tissue water contents.

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>3h</th>
<th>6h</th>
<th>12h</th>
<th>24h</th>
<th>48h</th>
<th>72h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>1</td>
<td>67.14±0.00</td>
<td>68.37±0.01</td>
<td>69.59±0.01</td>
<td>70.68±0.00</td>
<td>69.38±0.00</td>
<td>68.46±0.00</td>
</tr>
<tr>
<td>MCAO</td>
<td>1</td>
<td>78.12±2.41</td>
<td>79.68±2.51</td>
<td>81.18±1.56</td>
<td>85.58±0.48</td>
<td>84.82±3.67</td>
<td>83.38±3.8</td>
</tr>
<tr>
<td>MCAO+Nrf2 Agonist</td>
<td>1</td>
<td>69.76±3.84</td>
<td>71.23±1.42</td>
<td>76.43±1.65</td>
<td>79.08±7.68</td>
<td>75.51±5.25</td>
<td>74.33±1.18</td>
</tr>
<tr>
<td>F-value</td>
<td></td>
<td>168.265</td>
<td>78.487</td>
<td>96.763</td>
<td>164.872</td>
<td>323.234</td>
<td>174.287</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Table IV. Determination of SOD in brain tissues of each group.

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>3h</th>
<th>6h</th>
<th>12h</th>
<th>24h</th>
<th>48h</th>
<th>72h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>1</td>
<td>117.14±3.98</td>
<td>118.37±0.98</td>
<td>116.59±0.01</td>
<td>117.68±0.00</td>
<td>115.38±1.69</td>
<td>116.4±1.43</td>
</tr>
<tr>
<td>MCAO</td>
<td>1</td>
<td>85.12±2.41</td>
<td>77.68±2.51</td>
<td>72.18±1.56</td>
<td>68.58±0.48</td>
<td>64.82±3.67</td>
<td>68.38±3.28</td>
</tr>
<tr>
<td>MCAO+Nrf2 agonist</td>
<td>1</td>
<td>116.76±2.84</td>
<td>101.23±1.48</td>
<td>99.43±2.65</td>
<td>89.08±7.68</td>
<td>85.51±3.85</td>
<td>78.33±1.18</td>
</tr>
<tr>
<td>F-value</td>
<td></td>
<td>198.265</td>
<td>1378.487</td>
<td>480.763</td>
<td>339.872</td>
<td>701.234</td>
<td>342.887</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>
These results showed that the Nrf2 agonist could significantly increase SOD activity, mitigate the damages caused by cerebral ischemia and have protective effects on cerebral ischemia.

Expression of HO-1 mRNA and Nrf2 and HO-1 protein in the brain tissues of each group

The expression of HO-1 mRNA did not change much with time in the sham group. Compared with the sham group, the MCAO showed increased HO-1 at 3h; the increase was significant at 12h and the HO-1 expression peaked at 48h. Compared with the sham group, the MCAO + Nrf2 agonists group had significantly higher Nrf2 and HO-1, and overtime, the expression continues to rise. Compared with the MCAO group, the MCAO + Nrf2 group had significantly lower HO-1 mRNA expression at each time point, and the differences were statistically significant (p<0.05) (Figures 6 and 7). The change of expression level of HO-1 and Nrf2 protein in each group on the above time point was significant. The expression levels of HO-1 protein in brain tissue of all time points were significantly decreased after treated with Nrf-2 agonist, while the Nrf-2 level was significantly improved, and the difference was statistically significant (p<0.05). The expression level of Nrf-2 at each time point was increased, and the expression level of HO-1 was reduced by using Nrf-2 agonist.

Discussion

Ischemia-reperfusion brain injury is a complicated pathological process. The underlying mechanisms connect and interact with one another. The injuries include primary injury during ischemia and secondary injury from reperfusion; while ischemia and hypoxia are the factors to initiate these injuries. To date, research results showed that a lot of mechanisms were involved in ischemia-reperfusion brain injury, and they were interrelated and affected one another. A variety of
Nrf2/HO-1 is a key signaling pathway in ischemia-reperfusion brain injury.

Inflammatory cytokines and signaling pathways seemed to be involved in the occurrence development of ischemia-reperfusion injury.

This study found that the MCAO group had larger infarct than the sham group. Also, they had decreased SOD activities at all time points compared to the sham group. These finding indicated that ischemia-reperfusion injury increased the oxidative stress. But Nrf2 agonist markedly improved the SOD activity with significant difference (p<0.05) and also improved the MCAO rats’ neurological functions. Previous studies suggested that, among all the biochemical reactions involving Nrf2, Nrf2’s interaction with protein kinase C (PKC) was more prominent. PKC belongs to the serine/threonine protein kinase family, and is widely present in the body cells. It is involved in cell skeleton, cell proliferation, differentiation, migration, and apoptosis. PKCα is the most prominent subtype in the PKC family. Studies have shown that PKCα could directly phosphorylate Nrf2, dissociate it with Kelch-like ECH-associated protein-1, promote its nuclear translocation so it could recognize and bind to ARE, thereby regulate the expression of its target genes. The Nrf2/heme oxygenase-1 (HO-1)

Figure 6. Protein expression of Nrf-2 and HO-1 detected by Western blotting. The Nrf2 agonists significantly decreased the HO-1 protein level, while the Nrf2 level was significantly increased, the differences were statistically significant (p<0.05). Nrf2 agonists may increase Nrf2 expression and decreased HO-1 expression.

Figure 7. Changes of HO-1 mRNA. The MCAO group had much higher HO-1 mRNA than the other groups. The sham group did not show much fluctuation of HO-1 mRNA. The MCAO + Nrf2 group significantly decreased the HO-1 mRNA.
pathway is an important intracellular anti-oxidative stress pathway. In ischemic tissue damages, over activation of this pathway could have some protective effects. The findings of this investigation also suggested that Nrf2 play a catalytic role in the hypoxic-ischemic brain injury model. Appropriate activation of Nrf2 can improve the prognosis of the disease and has some clinical significances.

Conclusions

We observed that the Nrf-2 agonists could protect brain function by increasing Nrf-2 level after ischemia-reperfusion injury.

Conflict of interest

Authors have no conflict of interest.

References


14) HOSSEINZADEH H, SADEGHNA HR. Safranal, a constituent of Crocus sativus (safron), attenuated cerebral ischemia induced oxidative damage in rat hippocampus. J Pharm Pharm Sci 2005; 8: 394-399.